Table 2 Clinical practices compared between PDAC, PanNEC and PanNET
| PDAC | PanNEC | PanNET | |
|---|---|---|---|
| Diagnosis | |||
| Serum test | CA199, CEA,CA125 |
NSE CA199, CEA, AFP |
CgA, 5-HIAA Functional hormone |
| Imaging |
Computer tomography Magnetic resonance imaging F18-FDG PET/CT |
Computer tomography Magnetic resonance imaging F18-FDG PET/CT |
Computer tomography Magnetic resonance imaging Ga68-DOTATATE PET/CT Somatostatin receptor scintigraphy |
| Therapy | |||
| Localized |
Resection Neoadjuvent chemo + resection | Resection |
Active surveillance Resection |
| Advanced and metastasis |
SYSTEM TREATMENT Irinotecan + Oxaliplatin + fluorouracil Gemcitabine + Albumin-Paclitaxel Clinical trials OTHERS Radiotherapy |
SYSTEM TREATMENT Etoposide + cisplatin Irinotecan + cisplatin Clinical trials OTHERS Radiotherapy |
LOCAL TREATMENT Debulking surgery Transarterial chemoembolization, Ablation of liver metastasis SYSTEM TREATMENT Somatostatin analogs Sunitinib and everolimus Temozolomidecapecitabine |
| Follow-up | 3 months | 3 months | Localized 6-12 months; Metastasis 3-6 months |